Stephens initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $39.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2025 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 11/15/2024 | $39.00 | Overweight | Stephens |
| 7/29/2024 | $47.00 | Overweight | KeyBanc Capital Markets |
| 7/16/2024 | Mkt Perform | JMP Securities | |
| 6/28/2024 | Outperform | William Blair | |
| 5/9/2023 | $55.00 | Buy | BTIG Research |
| 10/26/2021 | $65.00 → $53.00 | Hold → Buy | Craig Hallum |
| 7/13/2021 | $95.00 → $54.00 | Outperform | Raymond James |
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
4 - Simulations Plus, Inc. (0001023459) (Issuer)
Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its third quarter fiscal 2025, ended May 31, 2025. Third Quarter 2025 Financial Highlights (as compared to third quarter 2024) Total revenue increased 10% to $20.4 million Software revenue increased 6% to $12.6 million, representing 62% of total revenue Services revenue increased 17% to $7.7 millio
Updates fiscal 2025 revenue guidance range Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue guidance. The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million Full year fiscal 2025 revenue is expected to range between $76 millio
Total revenue grew 23% year-over-year driven by strong growth in both software and services Maintains full-year revenue guidance of $90 to $93 million and adjusted diluted EPS of $1.07 to $1.20 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025. Second Quarter 2025 Financial Highlights (as compared to second quarter 2024) Total revenue increased 23% to $22.4 million Software revenue increased 16% to $13.5 million, repres
KeyBanc Capital Markets downgraded Simulations Plus from Overweight to Sector Weight
Stephens initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $39.00
KeyBanc Capital Markets initiated coverage of Simulations Plus with a rating of Overweight and set a new price target of $47.00
Investment to accelerate innovations in biopharma development through Corporate Development Initiative Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced an investment of $1 million in technology company Nurocor. Founded in 2017, Nurocor offers a cloud-based software platform designed to improve efficiency, reusability, governance, and automation for pharmaceutical companies through digitalization in the clinical development phase. Its solution significantly accelerates the typical clinical trial lif
Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its third quarter fiscal 2025, ended May 31, 2025. Third Quarter 2025 Financial Highlights (as compared to third quarter 2024) Total revenue increased 10% to $20.4 million Software revenue increased 6% to $12.6 million, representing 62% of total revenue Services revenue increased 17% to $7.7 millio
Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in the Citizens Medical Devices and Healthcare Services Forum taking place in Boston, Massachusetts. Mr. O'Connor will host one-on-one meetings with institutional investors on Tuesday, June 17, 2025. For more information about the events or questions about registration, interested parties should reach out to their contacts at Citizens. About Simulations Plus, Inc. With more
10-Q - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
8-K - Simulations Plus, Inc. (0001023459) (Filer)
QHP Capital, L.P. ("QHP"), an investor in technology and services companies in the life sciences and healthcare sectors, today announced its sale of Pro-ficiency, LLC ("Pro-ficiency" or the "Company"), a leader in providing tech-enabled training and compliance solutions for clinical trial investigators and site staff, to Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy. Michael Raymer, Chief Executive Officer of Pro-ficiency, said, "We are excited to join the Simulations Plus team, which has a well-established and recognized leadership position in modeling and simulations wi
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), announced today the appointment of Will Frederick as chief financial officer (CFO), succeeding John Kneisel, who retires after seven years with the company. Will Frederick brings more than 25 years of financial leadership experience to the company. He has a proven track record of developing and implementing strategies to drive revenue growth, increase profitability, managing merger & acquisition activities and achieving corporate objectives. He has global experience with both publicly traded and privately held companies including Pharsight, Entelos, Avaya, The Walt Disney Company and Ford Motor Company, among
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)
SC 13G/A - Simulations Plus, Inc. (0001023459) (Subject)